J. Goldman & CO LP Tarsus Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

$3.21 Billion
Q3 2024

A detailed history of J. Goldman & CO LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 557,500 shares of TARS stock, worth $26 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares

557,500

Previous 387,161 44.0%

Holding current value

$26 Million

Previous $10.5 Million 74.25%

% of portfolio

0.57%

Previous 0.32%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.54 - $34.6 $3.67 Million - $5.89 Million	170,339 Added 44.0%	557,500 $18.3 Million
Q2 2024 Aug 14, 2024	BUY	$25.17 - $38.73 $5.63 Million - $8.67 Million	223,814 Added 137.02%	387,161 $10.5 Million
Q1 2024 May 15, 2024	BUY	$19.61 - $39.22 $1.78 Million - $3.57 Million	91,003 Added 125.79%	163,347 $5.94 Million
Q4 2023 Feb 14, 2024	SELL	$12.98 - $20.73 $695,273 - $1.11 Million	-53,565 Reduced 42.54%	72,344 $1.46 Million
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $1.03 Million - $1.72 Million	69,937 Added 124.95%	125,909 $2.24 Million
Q2 2023 Aug 14, 2023	BUY	$11.57 - $19.63 $166,596 - $282,652	14,399 Added 34.64%	55,972 $1.01 Million
Q3 2022 Nov 14, 2022	SELL	$14.08 - $18.5 $130,282 - $171,180	-9,253 Reduced 18.21%	41,573 $712,000
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $446,324 - $768,580	40,282 Added 382.04%	50,826 $742,000
Q1 2022 May 16, 2022	BUY	$14.49 - $24.28 $152,782 - $256,008	10,544 New	10,544 $177,000
Q4 2021 Feb 14, 2022	SELL	$21.21 - $29.68 $470,819 - $658,836	-22,198 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.45 - $29.22 $247,811 - $337,578	-11,553 Reduced 34.23%	22,198 $478,000
Q2 2021 Aug 16, 2021	BUY	$27.16 - $38.59 $916,677 - $1.3 Million	33,751 New	33,751 $978,000

Others Institutions Holding TARS

# of Institutions

169

Shares Held

43.2M

Call Options Held

442K

Put Options Held

4.1K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.24B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account